Zobrazeno 1 - 10
of 185
pro vyhledávání: '"Adam P, Bress"'
Autor:
Yizhe Xu, Catherine G. Derington, Daniel K. Addo, Tao He, Joshua A. Jacobs, April F. Mohanty, Jaejin An, William C. Cushman, P. Michael Ho, Brandon K. Bellows, Jordana B. Cohen, Adam P. Bress
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 20 (2024)
Background Among patients diagnosed with high blood pressure (BP), initial dual therapy has been recommended for patients with high pretreatment systolic BP (≥160 mm Hg) since 2003, and first‐line β‐blocker use without a compelling condition h
Externí odkaz:
https://doaj.org/article/e25fb27abb434995bd67a0100bb57976
Autor:
Joshua A. Jacobs, PharmD, Spencer J. Carter, MD, Griffin Bullock, MD, Jessica R. Carey, PharmD, Irene Z. Pan, PharmD, M. Shea Kinsey, PharmD, MBA, MHSA, MS, Alexander R. Zheutlin, MD, MS, Chris J. Kapelios, MD, Shilpa Raju, MD, James C. Fang, MD, Kevin S. Shah, MD, Adam P. Bress, PharmD, MS
Publikováno v:
JACC: Advances, Vol 3, Iss 10, Pp 101250- (2024)
Background: Nearly one-half of patients admitted with acute decompensated heart failure (ADHF) are discharged with unresolved congestion, elevating rehospitalization risk. This may be due to suboptimal intravenous (IV) loop diuretic dosing, which may
Externí odkaz:
https://doaj.org/article/701d97fe4656429bac2ad24a4084cb01
Autor:
Jordan B. King, Swati Sakhuja, Catherine G. Derington, Paul Kolm, Jennifer S. Herrick, Ransmond O. Berchie, Jincheng Shen, Tom Greene, Gabriel S. Tajeu, George Howard, Emily B. Levitan, Paul Muntner, Monika M. Safford, Jian Ying, William S. Weintraub, Andrew E. Moran, Adam P. Bress, Brandon K. Bellows
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 18 (2024)
Externí odkaz:
https://doaj.org/article/206c72034fac4040b53b5df99c230961
Autor:
Joshua A. Jacobs, Alexander R. Zheutlin, Catherine G. Derington, Jordan B. King, Ambarish Pandey, Adam P. Bress
Publikováno v:
American Journal of Preventive Cardiology, Vol 17, Iss , Pp 100624- (2024)
Objective: Glucagon-like peptide-1 receptor agonists (GLP1-RAs) and sodium-glucose cotransporter 2 inhibitors (SGLT2Is) lower adverse cardiac and kidney events among high-risk patients with diabetes mellitus (DM) and are now guideline-recommended as
Externí odkaz:
https://doaj.org/article/ad0474e7480e4f4f81cd08016de4521d
Autor:
Alexander R. Zheutlin, Nasser Sharareh, Jenny S. Guadamuz, Ransmond O. Berchie, Catherine G. Derington, Joshua A. Jacobs, Favel L. Mondesir, G. Caleb Alexander, Emily B. Levitan, Monika Safford, Robert O. Vos, Dima M. Qato, Adam P. Bress
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 5 (2024)
Background Poor neighborhood‐level access to health care, including community pharmacies, contributes to cardiovascular disparities in the United States. The authors quantified the association between pharmacy proximity, antihypertensive and statin
Externí odkaz:
https://doaj.org/article/b9b50bd1dca2489399c69580e1c71e23
Autor:
Joshua A. Jacobs, Catherine G. Derington, Alexander R. Zheutlin, Jordan B. King, Jordana B. Cohen, John Bucheit, Ian M. Kronish, Daniel K. Addo, Donald E. Morisky, Tom H. Greene, Adam P. Bress
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 3 (2024)
Background Therapeutic inertia (TI), failure to intensify antihypertensive medication when blood pressure (BP) is above goal, remains prevalent in hypertension management. The degree to which self‐reported antihypertensive adherence is associated w
Externí odkaz:
https://doaj.org/article/b98473bd543d4897bec98b968786a497
Effectiveness of Hypertension Management Strategies in SPRINT‐Eligible US Adults: A Simulation Study
Autor:
Fengdi Zhang, Kelsey B. Bryant, Andrew E. Moran, Yiyi Zhang, Jordana B. Cohen, Adam P. Bress, James P. Sheppard, Jordan B. King, Catherine G. Derington, William S. Weintraub, Ian M. Kronish, Steven Shea, Brandon K. Bellows
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 2 (2024)
Background Despite reducing cardiovascular disease (CVD) events and death in SPRINT (Systolic Blood Pressure Intervention Trial), intensive systolic blood pressure goals have not been adopted in the United States. This study aimed to simulate the pot
Externí odkaz:
https://doaj.org/article/76664c805d6342f3b8120464eb9e9562
Autor:
William S. Weintraub, Deepak L. Bhatt, Zugui Zhang, Sarahfaye Dolman, William E. Boden, Adam P. Bress, Brandon K. Bellows, Catherine G. Derington, Sephy Philip, Gabriel Steg, Michael Miller, Eliot A. Brinton, Terry A. Jacobson, Jean‐Claude Tardif, Christie M. Ballantyne, Paul Kolm
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 1 (2024)
Background In 3146 REDUCE‐IT USA (Reduction of Cardiovascular Events With Icosapent Ethyl Intervention Trial USA) participants, icosapent ethyl (IPE) reduced first and total cardiovascular events by 31% and 36%, respectively, over 4.9 years of foll
Externí odkaz:
https://doaj.org/article/dc8430b3b4ce4e8a958569552e9dcca3
Autor:
Jordan B. King, Ransmond O. Berchie, Catherine G. Derington, Zachary A. Marcum, Daniel O. Scharfstein, Tom H. Greene, Jennifer S. Herrick, Joshua A. Jacobs, Alexander R. Zheutlin, Adam P. Bress, Jordana B. Cohen
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 17 (2023)
BACKGROUND Angiotensin II receptor blockers (ARBs) and angiotensin‐converting enzyme inhibitors (ACEIs) block distinct components of the renin‐angiotensin system. Whether this translates into differential effects on cardiovascular disease events
Externí odkaz:
https://doaj.org/article/a1a13064eddc40198740ba08ed6430a4
Autor:
Catherine G. Derington, Adam P. Bress, Jennifer S. Herrick, Joshua A. Jacobs, Alexander R. Zheutlin, Ransmond O. Berchie, Molly B. Conroy, William C. Cushman, Jordan B. King
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 11 (2023)
Background Fixed‐dose combination (FDC) antihypertensive products improve blood pressure control and adherence among patients with hypertension. It is unknown to what degree commercially available FDC products meet the current hypertension manageme
Externí odkaz:
https://doaj.org/article/a272e666eb7748f593b25f30788b8455